| Autor: |
Wu IE; Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan., Anggelia MR; Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung Memorial Medical College, Chang Gung University, Taoyuan 333, Taiwan., Lin SY; Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan., Chen CY; Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan., Chu IM; Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan., Lin CH; Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung Memorial Medical College, Chang Gung University, Taoyuan 333, Taiwan. |
| Abstrakt: |
Tacrolimus (FK506) is a common immunosuppressive drug that is capable of suppressing acute rejection reactions, and is used to treat patients after allotransplantation. A stable and suitable serum concentration of tacrolimus is desirable for better therapeutic effects. However, daily drug administration via oral or injection routes is quite inconvenient and may encounter drug overdose or low patient compliance problems. In this research, our objective was to develop an extended delivery system using a thermosensitive hydrogel of poly ethylene glycol, D,L-lactide (L), and ϵ-caprolactone (CL) block copolymer, mPEG-PLCL, as a drug depot. The formulation of mPEG-PLCL and 0.5% PVP-dissolved tacrolimus was studied and the optimal formulation was obtained. The in vivo data showed that in situ gelling is achieved, a stable and sustained release of the drug within 30 days can be maintained, and the hydrogel was majorly degraded in that period. Moreover, improved allograft survival was achieved. Together, these data imply the potential of the current formulation for immunosuppressive treatments. |
